Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer

Trenti, Emanuela; D’Elia, Carolina; Mian, Christine; Schwienbacher, Christine; Hanspeter, Esther; Pycha, A.; Kafka, Mona; Degener, Stephan; Danuser, Hansjörg; Roth, Stephan; Pycha, Armin

doi:10.1002/cncy.22152

Cited by 35 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EpiCheck presented higher sensitivity with a lower specificity when compared with cytology (62.3% vs. 33.3% and 86.3% vs. 98.6%, respectively). Similarly, EpiCheck was more sensitive in high-grade tumors, where the obtained NPV in this study was 82.9% [67]. As a pitfall, EpiCheck is costly and technically challenging in execution, but unlike other tests, the presence of inflammation in the urinary tract did not affect the sensitivity and specificity of EpiCheck [64,67].…”

Section: Epicheckmentioning

confidence: 52%

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by invasive tests, namely periodic cystoscopies; this procedure, although a reliable method, is highly uncomfortable for the patient and it is not exempt of comorbidities. Currently, there is no formal indication for the use of molecular biomarkers in clinical practice, even though there are several tests available. There is an imperative need for a clinical non-invasive testing for early detection, disease monitoring, and treatment response in BC. In this review, we aim to assess and compare different tests based on molecular biomarkers and evaluate their potential role as new molecules for bladder cancer diagnosis, follow-up, and treatment response monitoring.

show abstract

Section: Epicheckmentioning

confidence: 52%

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…During the study by Trenti et al [12], BE was tested on 243 patients, with 215 evaluable results (28 test failures excluded from the final analysis). Sixty-nine (32%) patients had an NMIBC recurrence.…”

Section: Results: Sensitivity Specificity and Predictive Values Anamentioning

confidence: 99%

“…Few studies have compared the sensitivity, PPV and NPV for both cytology and BE, and only one evaluated the diagnostic accuracy of the combination of the two tests [12].…”

Section: Results: Be and Cytologymentioning

confidence: 99%

See 1 more Smart Citation

The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence

Mancini

Righetto

Zumerle

et al. 2020

IJMS

View full text Add to dashboard Cite

Recently, there has been a great effort to develop tests based on non-invasive urinary biomarkers (NMIBCs). These tests are based on the fact that NMIBCs are heterogeneous at the molecular level and can be divided into different molecular groups useful to predict prognosis and response to treatment. The assessment of epigenetic alterations, such as DNA methylation, represents a promising cancer biomarker. DNA methylation is an epigenetic modification that affects gene expression without modifying the DNA sequence. Several studies have highlighted the presence of methylated loci in the context of bladder cancer, indicating its potential application as a diagnostic and prognostic biomarker. One of the novel assays based on a DNA methylation profile, the Bladder EpiCheck, analyzes DNA from spontaneous urine, detecting disease-specific DNA methylation patterns in bladder cancer patients. This test, due to its non-invasive nature and highly promising performance could, in future, become an invaluable tool in the follow-up of bladder cancer patients. Potential new applications could include diagnosis and surveillance of upper-tract disease, for the replacement of invasive testing and ureteroscopy.

show abstract

“…Bladder cancer is a common cancer of the urinary system and the ninth most common malignant tumor in the world [1]. The presence of bladder cancer cells in the urine provides important evidence for bladder cancer diagnosis [2]. One of the reasons for the low sensitivity of urine cytology is the interference of background cells and other impurities [3].…”

Section: Introductionmentioning

confidence: 99%

A Microfluidic Detection System for Bladder Cancer Tumor Cells

Zhao

et al. 2019

Micromachines

View full text Add to dashboard Cite

The clinical characteristics of excreted tumor cells can be found in the urine of bladder cancer patients, meaning the identification of tumor cells in urine can assist in bladder cancer diagnosis. The presence of white blood cells and epithelial cells in the urine interferes with the recognition of tumor cells. In this paper, a technique for detecting cancer cells in urine based on microfluidics provides a novel approach to bladder cancer diagnosis. The bladder cancer cell line (T24) and MeT-5A were used as positive bladder tumor cells and non-tumor cells, respectively. The practicality of the tumor cell detection system based on microfluidic cell chip detection technology is discussed. The tumor cell (T24) concentration was around 1 × 10 4 to 300 × 10 4 cells/mL. When phosphate buffer saline (PBS) was the diluted solution, the tumor cell detected rate was 63-71% and the detection of tumor cell number stability (coefficient of variation, CV%) was 6.7-4.1%, while when urine was the diluted solution, the tumor cell detected rate was 64-72% and the detection of tumor cell number stability (CV%) was 6.3-3.9%. In addition, both PBS and urine are tumor cell dilution fluid solutions. The sample was analyzed at a speed of 750 microns per hour. Based on the above experiments, a system for detecting bladder cancer cells in urine by microfluidic analysis chip technology was reported. The rate of recognizing bladder cancer cells reached 68.4%, and the speed reached 2 mL/h.

show abstract

Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancer

Cited by 35 publications

References 21 publications

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence

A Microfluidic Detection System for Bladder Cancer Tumor Cells

Contact Info

Product

Resources

About